Because loss of NMT2 protein in breast cancer favored better patient prognosis, we investigated whether breast cancer cells were susceptible to NMT inhibition using the pan-NMT inhibitor PCLX-001 both in vitro, and in an in vivo animal model. Here, NMT1 is linked to breast carcinoma.